Cargando…

Survival analysis in lung cancer patients with interstitial lung disease

OBJECTIVE: Lung cancer patients with interstitial lung disease (ILD) are prone for higher morbidity and mortality and their treatment is challenging. The purpose of this study is to investigate whether the survival of lung cancer patients is affected by the presence of ILD documented on CT. MATERIAL...

Descripción completa

Detalles Bibliográficos
Autores principales: Alomaish, Hassan, Ung, Yee, Wang, Stella, Tyrrell, Pascal N., Zahra, Saly Abo, Oikonomou, Anastasia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423282/
https://www.ncbi.nlm.nih.gov/pubmed/34492020
http://dx.doi.org/10.1371/journal.pone.0255375
_version_ 1783749434802176000
author Alomaish, Hassan
Ung, Yee
Wang, Stella
Tyrrell, Pascal N.
Zahra, Saly Abo
Oikonomou, Anastasia
author_facet Alomaish, Hassan
Ung, Yee
Wang, Stella
Tyrrell, Pascal N.
Zahra, Saly Abo
Oikonomou, Anastasia
author_sort Alomaish, Hassan
collection PubMed
description OBJECTIVE: Lung cancer patients with interstitial lung disease (ILD) are prone for higher morbidity and mortality and their treatment is challenging. The purpose of this study is to investigate whether the survival of lung cancer patients is affected by the presence of ILD documented on CT. MATERIALS AND METHODS: 146 patients with ILD at initial chest CT were retrospectively included in the study. 146 lung cancer controls without ILD were selected. Chest CTs were evaluated for the presence of pulmonary fibrosis which was classified in 4 categories. Presence and type of emphysema, extent of ILD and emphysema, location and histologic type of cancer, clinical staging and treatment were evaluated. Kaplan-Meier estimates and Cox regression models were used to assess survival probability and hazard of death of different groups. P value < 0.05 was considered significant. RESULTS: 5-year survival for the study group was 41% versus 48% for the control group (log-rank test p = 0.0092). No significant difference in survival rate was found between the four different categories of ILD (log-rank test, p = 0.195) and the different histologic types (log-rank test, p = 0.4005). A cox proportional hazard model was used including presence of ILD, clinical stage and age. The hazard of death among patients with ILD was 1.522 times that among patients without ILD (95%CI, p = 0.029). CONCLUSION: Patients with lung cancer and CT evidence of ILD have a significantly shorter survival compared to patients with lung cancer only. Documenting the type and grading the severity of ILD in lung cancer patients will significantly contribute to their challenging management.
format Online
Article
Text
id pubmed-8423282
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-84232822021-09-08 Survival analysis in lung cancer patients with interstitial lung disease Alomaish, Hassan Ung, Yee Wang, Stella Tyrrell, Pascal N. Zahra, Saly Abo Oikonomou, Anastasia PLoS One Research Article OBJECTIVE: Lung cancer patients with interstitial lung disease (ILD) are prone for higher morbidity and mortality and their treatment is challenging. The purpose of this study is to investigate whether the survival of lung cancer patients is affected by the presence of ILD documented on CT. MATERIALS AND METHODS: 146 patients with ILD at initial chest CT were retrospectively included in the study. 146 lung cancer controls without ILD were selected. Chest CTs were evaluated for the presence of pulmonary fibrosis which was classified in 4 categories. Presence and type of emphysema, extent of ILD and emphysema, location and histologic type of cancer, clinical staging and treatment were evaluated. Kaplan-Meier estimates and Cox regression models were used to assess survival probability and hazard of death of different groups. P value < 0.05 was considered significant. RESULTS: 5-year survival for the study group was 41% versus 48% for the control group (log-rank test p = 0.0092). No significant difference in survival rate was found between the four different categories of ILD (log-rank test, p = 0.195) and the different histologic types (log-rank test, p = 0.4005). A cox proportional hazard model was used including presence of ILD, clinical stage and age. The hazard of death among patients with ILD was 1.522 times that among patients without ILD (95%CI, p = 0.029). CONCLUSION: Patients with lung cancer and CT evidence of ILD have a significantly shorter survival compared to patients with lung cancer only. Documenting the type and grading the severity of ILD in lung cancer patients will significantly contribute to their challenging management. Public Library of Science 2021-09-07 /pmc/articles/PMC8423282/ /pubmed/34492020 http://dx.doi.org/10.1371/journal.pone.0255375 Text en © 2021 Alomaish et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Alomaish, Hassan
Ung, Yee
Wang, Stella
Tyrrell, Pascal N.
Zahra, Saly Abo
Oikonomou, Anastasia
Survival analysis in lung cancer patients with interstitial lung disease
title Survival analysis in lung cancer patients with interstitial lung disease
title_full Survival analysis in lung cancer patients with interstitial lung disease
title_fullStr Survival analysis in lung cancer patients with interstitial lung disease
title_full_unstemmed Survival analysis in lung cancer patients with interstitial lung disease
title_short Survival analysis in lung cancer patients with interstitial lung disease
title_sort survival analysis in lung cancer patients with interstitial lung disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423282/
https://www.ncbi.nlm.nih.gov/pubmed/34492020
http://dx.doi.org/10.1371/journal.pone.0255375
work_keys_str_mv AT alomaishhassan survivalanalysisinlungcancerpatientswithinterstitiallungdisease
AT ungyee survivalanalysisinlungcancerpatientswithinterstitiallungdisease
AT wangstella survivalanalysisinlungcancerpatientswithinterstitiallungdisease
AT tyrrellpascaln survivalanalysisinlungcancerpatientswithinterstitiallungdisease
AT zahrasalyabo survivalanalysisinlungcancerpatientswithinterstitiallungdisease
AT oikonomouanastasia survivalanalysisinlungcancerpatientswithinterstitiallungdisease